TB-500: What the Research Does and Doesn't Show

TB-500 is marketed heavily in recovery and injury circles, usually with confident claims about healing tendons, muscles, and wounds. Cutting through that requires separating two different things: what the underlying biology suggests, and what has actually been tested in humans. With TB-500, the gap between those two is enormous.

What TB-500 actually is

TB-500 is a synthetic peptide based on a fragment of thymosin beta-4 (Tβ4), a naturally occurring ~43-amino-acid protein involved in actin binding, cell migration, blood vessel formation, and tissue repair. The fragment most often sold (the actin-binding sequence Ac-LKKTETQ, residues 17–23) is not the same molecule as the full Tβ4 protein that drug developers studied — yet the two are routinely discussed as interchangeable, which is the root of much of the confusion.

The biological rationale is reasonable. Thymosin beta-4 binds actin, and in laboratory and animal models it supports wound closure, angiogenesis, and reduced scarring.

The honest limit: a strong preclinical rationale and animal signal is exactly where many promising compounds stall. The human trials that exist studied the full Tβ4 protein applied topically for eye disease — not the injected TB-500 fragment for athletic recovery.

What the research does show

• In animal models, thymosin beta-4 has promoted wound healing, cardiac repair, and corneal healing.
• The full Tβ4 protein (developed by RegeneRx as RGN-259) has reached human trials in ophthalmology. A small randomized, double-masked, placebo-controlled phase 2 trial in severe dry eye (Sosne et al., Cornea, 2015; 9 patients) reported a 35.1% reduction in ocular discomfort and a 59.1% reduction in corneal staining versus vehicle.
• The mechanism is well enough characterized to make the interest understandable.

What the research does not show

• No substantial, well-controlled human trials of the injected TB-500 fragment for athletic injury, tendon, or muscle recovery.
• No established dosing, purity, or long-term safety data in humans for the gray-market product.
• No demonstration that dramatic animal repair results translate to systemic injury recovery in people.

Full protein versus the fragment being sold

	Thymosin beta-4 (full protein)	TB-500 (fragment)
Size	~43 amino acids	7 residues (LKKTETQ, 17–23)
Human trials	Yes — topical, ophthalmology (RGN-259)	None identified by the FDA
Best human result	35.1% reduction in ocular discomfort, phase 2, 9 patients	—
Route studied	Topical, to the eye	Injected, in unregulated use
Regulatory status	Investigational drug candidate	Not approved; flagged by FDA for compounding risks

The two columns are routinely collapsed into one in marketing copy. They are not the same molecule, they were not studied by the same route, and only one of them has human data at all.

What the FDA says about it

This is worth quoting rather than paraphrasing, because the agency addresses the exact fragment being sold rather than the parent protein. In its review of substances nominated for compounding, the FDA lists “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500” and states that such preparations “may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impurities.”

Then the sentence that settles the evidence question: “FDA has not identified any human exposure data drug products containing Thymosin Beta-4, Fragment.”

That is a regulator saying, in 2026, that it could not find human data on the compound. It is a stronger statement than “the evidence is thin,” and it comes from the body whose job is to look.

The practical reality

Most TB-500 sold is unregulated and of uncertain purity, and it is prohibited in sport at all times by the World Anti-Doping Agency under Section S2 (peptide hormones, growth factors, and mimetics). That matters beyond elite athletics — “at all times” means in and out of competition, and tested amateurs are covered by the same list.

None of this means the molecule is useless; it means the confident recovery claims attached to it run far ahead of the human evidence.

Frequently asked questions

What does TB-500 do?

In animal and laboratory models, thymosin beta-4 binds actin and supports wound closure, blood vessel formation, and reduced scarring. What TB-500 does in humans is a different question, and the FDA’s own review states it “has not identified any human exposure data” for the fragment.

Is TB-500 the same as thymosin beta-4?

No, and the distinction is the single most misunderstood thing about it. TB-500 is a short fragment — the actin-binding sequence LKKTETQ, residues 17–23 — while thymosin beta-4 is the full ~43-amino-acid protein. The human trials people cite studied the full protein, applied topically for eye disease, not the injected fragment.

Is TB-500 legal?

It is not an approved drug, and it is not approved for human use. The FDA has flagged it among bulk substances that may present significant safety risks in compounding. It is also prohibited in sport at all times under WADA’s S2 category, so a tested athlete using it is doping regardless of intent.

TB-500 vs BPC-157 — which is better for injury?

Neither has controlled human trials supporting injury recovery, so “better” cannot be answered from evidence. Both appear on the FDA’s list of substances flagged for immunogenicity and impurity concerns. The comparison is drawn out in BPC-157 vs TB-500.

What are TB-500’s side effects?

Unknown in any rigorous sense, which is itself the finding. With no human exposure data identified by the FDA, there is no adverse-event profile to report — an absence of documented side effects is not evidence of safety, it is evidence that nobody has looked systematically.

Does TB-500 work for tendon injuries?

The animal data on tissue repair is real and is why the compound attracts interest. No controlled human trial has tested the injected fragment for tendon, muscle, or athletic injury. Claims about what it does for tendons in people are extrapolated from rodent studies rather than measured.

The takeaway

TB-500 sits on a real and intriguing scientific foundation, which is precisely why it is easy to oversell. The preclinical work is genuine, and the full Tβ4 protein has shown topical benefit in a small eye-disease trial. But human evidence for the injectable recovery benefits people buy it for is essentially absent. Until that changes, treat it as an experimental, sport-banned compound with an unproven risk-benefit profile.

Sources

• Sosne et al. (2015), “Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial,” Cornea — PubMed
• FDA — Certain bulk drug substances used in compounding may present significant safety risks — names “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500” and states the agency “has not identified any human exposure data” for it.
• World Anti-Doping Agency — Prohibited List — TB-500 falls under S2, prohibited at all times.